Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Med Oncol ; 40(1): 27, 2022 Dec 02.
Article in English | MEDLINE | ID: mdl-36459301

ABSTRACT

Cancer is one of the most challenging diseases to manage. A sizeable number of researches are done each year to find better diagnostic and therapeutic strategies. At the present time, a package of chemotherapy, targeted therapy, radiotherapy, and immunotherapy is available to cope with cancer cells. Regarding chemo-radiation therapy, low effectiveness and normal tissue toxicity are like barriers against optimal response. To remedy the situation, some agents have been proposed as adjuvants to improve tumor responses. Statins, the known substances for reducing lipid, have shown a considerable capability for cancer treatment. Among them, atorvastatin as a reductase (HMG-CoA) inhibitor might affect proliferation, migration, and survival of cancer cells. Since finding an appropriate adjutant is of great importance, numerous studies have been conducted to precisely unveil antitumor effects of atorvastatin and its associated pathways. In this review, we aim to comprehensively review the most highlighted studies which focus on the use of atorvastatin in cancer therapy.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors , Neoplasms , Radiation Oncology , Humans , Atorvastatin/pharmacology , Atorvastatin/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Immunotherapy , Adjuvants, Immunologic , Neoplasms/drug therapy
2.
Future Oncol ; 17(10): 1219-1235, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33593084

ABSTRACT

Radioprotection is the process whereby biological systems are aided against undesirable radiation hazards. Primitive radioprotectors suffered from either having crucial side effects or low efficacy in clinical applications. Therefore, the search for less toxic but more capable radioprotectants has continued for decades. Peptides have been investigated as radioprotectants in a variety of preclinical models both in vitro and in vivo. Peptides exert their influence through scavenging free radicals, modifying cell signaling and inhibiting cell apoptosis. Demonstrating potential in vivo properties, peptide radiation countermeasures might find enough credit for use in humans in the future. This article reviews the potential therapeutic value of currently known radioprotective peptides and attempts to provide a comprehensive source for further scientific research in this area.


Subject(s)
Peptides/pharmacology , Radiation Injuries/drug therapy , Radiation Injuries/etiology , Radiation, Ionizing , Radiation-Protective Agents/pharmacology , Animals , Drug Evaluation, Preclinical , Humans , Peptides/therapeutic use , Radiation-Protective Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL